Sun Pharma Advanced Research Co
129.40
-2.43(-1.84%)
Market Cap₹4,277.90 Cr
PE Ratio-14.11
IndustryHealthcare
Company Performance:
1D-1.84%
1M-10.33%
6M-13.69%
1Y-38.39%
5Y-22.75%
View Company Insightsright
Latest news about Sun Pharma Advanced Research Co
SPARC Reports Narrower Net Loss in Q1 Despite Revenue Decline Aug 04, 2025
Sun Pharma Advanced Research Co (SPARC) reported Q1 financial results with a reduced net loss of ₹518.70 crore, down from ₹959.00 crore in the previous year, despite a 42.70% revenue decline to ₹96.40 crore. Total expenses decreased to ₹705.90 crore from ₹1,138.70 crore. The company recorded other income of ₹91.40 crore. Key expenses included employee benefits (₹313.20 crore), clinical trials (₹55.40 crore), professional charges (₹100.70 crore), and finance costs (₹61.90 crore). SPARC operates in the Pharmaceutical Research and Development segment and maintains its 'Going Concern' status with support from its promoter group entity.
SPARC Shares Plummet 19% as Psoriasis Drug Fails Phase 2 Trials Jun 04, 2025
Sun Pharma Advanced Research Company: Psoriasis Drug Fails Phase 2 Trials, Shares Plummet Jun 04, 2025
Sun Pharma Advanced Research to Discuss Fund Raising Proposal in Upcoming Board Meeting May 12, 2025
SPARC Advances Cancer Treatment: IND Application for SBO-154 Submitted to FDA Mar 31, 2025